Roflumilast
- Level
- Commodity
- Parent
- 51161700
- Below
- 0
- Links · KBLI
- 9
Definition
UNSPSC 51161720This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H14Cl2F2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0P6C6ZOP5U, chemically known as 3-cyclopropylmethoxy-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide but generally known as roflumilast, which bears US NIH Compound Identifier 449193. European Medicines Agency schedules Roflumilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10358MIG. The term ROFLUMILAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 1 1998, List 39). World Health Organization schedules roflumilast in its Anatomical Therapeutic Chemical (ATC) Classification. ROFLUMILAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roflumilast under HS 29333999 and SITC 51574. As of Q4 2014, ROFLUMILAST remains the US FDA Preferred Term for this commodity. Roflumilast bears US NLM identifiers UMLS ID C0965618 and NCI Concept Code C76890. SMILES: CLC1C(NC(=O)C2CC(OCC3CC3)C(OC(F)F)CC2)C(CL)CNC1.
Same parent
Under 51161700 · 27Activities that produce or sell this
KBLI · 9Inherited from family 51160000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.